{"id":"NCT02046369","sponsor":"Sumitomo Pharma America, Inc.","briefTitle":"Lurasidone Pediatric Bipolar Study","officialTitle":"A Randomized, 6-Week, Double-blind, Placebo-Controlled, Flexible Dose, Parallel-Group Study to Evaluate the Efficacy and Safety of Lurasidone in Children and Adolescent Subjects With Bipolar I Depression","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-03","primaryCompletion":"2016-10","completion":"2016-10","firstPosted":"2014-01-27","resultsPosted":"2017-12-20","lastUpdate":"2017-12-20"},"enrollment":350,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Bipolar I Depression"],"interventions":[{"type":"DRUG","name":"Lurasidone","otherNames":["Latuda"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Luradisone","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"A study to evaluate efficacy and safety of flexibly dosed Lurasidone in children and adolescents with bipolar I depression","primaryOutcome":{"measure":"Change in the Children's Depression Rating Scale, Revised (CDRS-R) Total Score as Compared to Placebo From Double-Blind Baseline to Week 6 (Day 43) Baseline","timeFrame":"baseline, Week 6","effectByArm":[{"arm":"Luradisone","deltaMin":59.2,"sd":8.24},{"arm":"Placebo","deltaMin":58.6,"sd":8.26}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"10 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":39},"locations":{"siteCount":66,"countries":["United States","Bulgaria","Colombia","France","Hungary","Mexico","Philippines","Poland","Puerto Rico","South Korea","Ukraine"]},"refs":{"pmids":["29173735"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":175},"commonTop":["headache","nausea","somnolence","dizziness","vomiting"]}}